China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA vaccine SYS6006, which has completed six clinical trials demonstrating safety and efficacy across different age groups and vaccination scenarios.
Trial Highlights
- SYS6006-001: Enrolled 18–59-year-olds, showing good safety and strong neutralizing activity against WT, Delta, BA.2, and BA.5 variants.
- SYS6006-002: Targeted individuals aged 60+, with results indicating favorable safety.
- SYS6006-003: Confirmed a robust safety profile in 18+ participants, consistent with Phase I data.
- SYS6006-IIT003: Showed super-high immunogenicity and neutralizing activity against BA.2, with advantages as a booster against mutants.
- SYS6006-007: Initiated in August 2022, focusing on safety and efficacy.
- Booster Study: Assesses sequential or homologous booster immunization, progressing well under the State Council’s guidance.
Vaccine Profile
SYS6006 is designed with antigenic mutations targeting prevalent strains. Preclinical data show efficacy against Omicron and Delta, with immune protection via humoral and cellular responses, and memory B cell generation for long-term immunity. The vaccine received Chinese clinical trial approval in June 2022.-Fineline Info & Tech
